Latest News
FDA grants priority review to Bristol Myers Squibb's Opdivo regimen for advanced Hodgkin lymphoma
11 December 2025 - Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced on Thursday that the US Food and Drug Administration (FDA) has accepted and granted priority review to its supplemental Biologics License Application (sBLA) for Op...
Physiomics secures new contract with Numab Therapeutics for preclinical antibody development
11 December 2025 - Physiomics plc (AIM:PYC), a mathematical modelling, data science and biostatistics company, said on Thursday that it has signed a new contract with Swiss biotechnology company Numab Therapeutics AG to support preclinical developmen...
OTR Therapeutics agrees strategic collaboration and licence agreement with Zealand Pharma A/S
11 December 2025 - Chinese biotechnology company OTR Therapeutics announced on Thursday that it has signed a multi-programme strategic collaboration and licence agreement with Zealand Pharma A/S (CPH:ZEAL), a Danish biotechnology company focused on m...
Privo Technologies doses first patient in first-in-human clinical trial of PRV131
11 December 2025 - Privo Technologies Inc, a US-based, late-stage clinical biopharmaceutical company, announced on Thursday that the first patient has been dosed in its first-in-human clinical trial assessing PRV131, a nanoengineered intratumoural ci...
Senhwa Biosciences signs clinical supply agreement with BeOne Medicines
11 December 2025 - Senhwa Biosciences Inc (TPEx: 6492), a Taiwan-based clinical-stage biopharmaceutical company, announced on Thursday that it has signed a clinical supply agreement with BeOne Medicines, a US-based global oncology company.This agreem...